Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898–909.

Article  CAS  PubMed  Google Scholar 

Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020;84(9):1610–71.

Article  PubMed  Google Scholar 

Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood. 2020;136(23):2620–7.

Article  CAS  PubMed  Google Scholar 

Kyle RA, Greipp PR, O’Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68(1):220–4.

Article  CAS  PubMed  Google Scholar 

Milani P, Merlini G, Palladini G. light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10(1): e2018022.

Article  PubMed  PubMed Central  Google Scholar 

Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–18.

Article  CAS  PubMed  Google Scholar 

Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.

Article  PubMed  PubMed Central  Google Scholar 

Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, et al. Frequency of and prognostic significance of cardiac involvement at presentation in hereditary transthyretin-derived amyloidosis and the value of N-terminal Pro-B-type natriuretic peptide. Am J Cardiol. 2018;121(1):107–12.

Article  CAS  PubMed  Google Scholar 

Kristen AV, Scherer K, Buss S, Aus Dem Siepen F, Haufe S, Bauer R, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(5):502–10.

Article  PubMed  Google Scholar 

Takashio S, Yamada T, Nishi M, Morioka M, Fujiyama A, Nakashima N, et al. Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. J Cardiol. 2022;79(1):50–7.

Article  PubMed  Google Scholar 

Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective. Observational Cohort Study Circ. 2016;133(3):282–90.

CAS  Google Scholar 

Yamada T, Takashio S, Arima Y, Nishi M, Morioka M, Hirakawa K, et al. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail. 2020;7:2829.

Article  PubMed  PubMed Central  Google Scholar 

Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52(4):347–61.

Article  PubMed  Google Scholar 

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–16.

Article  CAS  PubMed  Google Scholar 

Ichikawa Y, Oota E, Odajima S, Kintsu M, Todo S, Takeuchi K, et al. Impact of tafamidis on echocardiographic cardiac function of patients with transthyretin cardiac amyloidosis. Circ J. 2023;87(4):508–16.

Article  CAS  PubMed  Google Scholar 

Kuyama N, Takashio S, Oguni T, Yamamoto M, Hirakawa K, Ishii M, et al. Cardiac biomarker change at 1 year after tafamidis treatment and clinical outcomes in patients with transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2024;13(10): e034518.

Article  PubMed  PubMed Central  Google Scholar 

Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, et al. Early experience of Tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. Circ J. 2022;86(7):1121–8.

Article  CAS  PubMed  Google Scholar 

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.

Article  CAS  PubMed  Google Scholar 

Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association. Circulation. 2020;142(1):e7–22.

Article  PubMed  Google Scholar 

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554–68.

Article  PubMed  PubMed Central  Google Scholar 

Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076–126.

Article  PubMed  Google Scholar 

Nishi M, Takashio S, Morioka M, Fujiyama A, Nakashima N, Hirakawa K, et al. Extracardiac biopsy sensitivity in transthyretin amyloidosis cardiomyopathy patients with positive (99 m)Tc-labeled pyrophosphate scintigraphy findings. Circ J. 2022;86(7):1113–20.

Article  CAS  PubMed  Google Scholar 

Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(4):909–20.

Article  PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J. 2022;43(41):4229–361.

Article  PubMed  Google Scholar 

Koyama J, Ikeda S, Ikeda U. Echocardiographic assessment of the cardiac amyloidoses. Circ J. 2015;79(4):721–34.

Article  PubMed  Google Scholar 

Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10.

Article  CAS  PubMed  Google Scholar 

Borer JS, Henry WL, Epstein SE. Echocardiographic observations in patients with systemic infiltrative disease involving the heart. Am J Cardiol. 1977;39(2):184–8.

Article  CAS  PubMed  Google Scholar 

Child JS, Krivokapich J, Abbasi AS. Increased right ventricular wall thickness on echocardiography in amyloid infiltrative cardiomyopathy. Am J Cardiol. 1979;44(7):1391–5.

Article  CAS  PubMed  Google Scholar 

Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981;63(1):188–96.

Article  CAS  PubMed  Google Scholar 

Chew C, Ziady GM, Raphael MJ, Oakley CM. The functional defect in amyloid heart disease. The “stiff heart” syndrome. Am J Cardiol. 1975;36(4):438–44.

Article  CAS  PubMed  Google Scholar 

Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992;13(5):623–7.

Article  CAS  PubMed  Google Scholar 

Ota S, Izumiya Y, Kitada R, Nishi T, Taruya A, Wada T, et al. Diagnostic significance of paradoxical left ventricular hypertrophy in detecting cardiac amyloidosis. Int J Cardiol Heart Vasc. 2023;49: 101279.

PubMed  PubMed Central